OPDIVO
PeakmAbBLAINJECTIONINJECTABLEPriority Review
Approved
Mar 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
5/8 — Partial
Priority Review
OPDIVO by Bristol Myers Squibb is pd-1 ligands, pd-l1 and pd-l2, to the pd-1 receptor found on t cells, inhibits t-cell proliferation and cytokine production. Approved for combination with ipilimumab for the treatment of renal cell carcinoma, combination with ipilimumab for the treatment of unresectable, metastatic melanoma and 6 more indications. First approved in 2015.
Drug data last refreshed 2h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPDIVO (nivolumab) is a human IgG4 monoclonal antibody that blocks PD-1 receptor signaling to release immune checkpoint inhibition and enable T-cell anti-tumor activity. It is approved across multiple solid tumors including melanoma, NSCLC, renal cell carcinoma, hepatocellular carcinoma, colorectal cancer, and esophageal cancer, primarily in combination with ipilimumab. The mechanism restores immune surveillance by preventing tumor-mediated suppression of T-cell proliferation and cytokine production.
$0.051BPart D
PeakOPDIVO is in peak commercial stage with established market presence; teams are focused on maximizing indication penetration and managing competitive erosion rather than rapid growth.
Mechanism of Action
PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Nivolumab…
Worked on OPDIVO at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.